

Enfuvirtide

Please disseminate this information to the appropriate individuals within your organisation:

Dear Colleague,

The Minister for Health and Social Services has endorsed AWMSG's recommendation to support the use of enfuvirtide within NHS Wales for the treatment of patients with HIV-1. It has been agreed the following restrictions should apply to its use:

1. Enfuvirtide should only be available to physicians in secondary care specialising in the management of patients with HIV.
2. Enfuvirtide must be used in accordance with criteria defined in the product's SPC and the UK British HIV Association (BHIVA) guidelines.

AWMSG would also like to draw the attention of prescribers to the following statement:

"AWMSG has concerns that reference in the Patient Product Information Sheet for enfuvirtide of returning vials to the pharmacy may be misinterpreted by patients and could result in them attempting to return a wider range of clinical waste to the pharmacy. Pharmacists, doctors and nurses may find it necessary to draw the attention of patients to the correct way to dispose of their clinical waste".

An update on all drugs appraised by AWMSG can be found by clicking on the following link:

<http://www.wales.nhs.uk/sites/documents/371/Appraisal%20work%20programme%20updated%2026%2E5%2E04%2Epdf>

Roger Walker
Chairman, AWMSG

Roger Walker BPharm PhD MRPharmS HonMFPH
Professor of Pharmacy Practice
Cardiff University
King Edward VII Avenue
Cardiff CF10 3XF

Tel: 029 20 875805
Email: walkerR@cardiff.ac.uk

and

Consultant in Pharmaceutical Public Health
National Public Health Service
Mamhilad Park Estate